In this episode of ATTD 2026 Conference Catch-Up, we dive into Scientific Parallel Session 01: Screening and Treatment Options for Delaying Onset of Type 1 Diabetes, featuring the latest research and clinical perspectives on early detection, risk stratification, and preventive interventions in Type 1 diabetes. Join us as we summarize key takeaways from these thought-provoking presentations: • Screening Programs for Type 1 Diabetes in the US: From Research to Standard of Care – Prof. Michael J. Haller (United States of America) • Could CGM Replace Antibodies Screening? – Prof. Boris Kovatchev, PhD (USA) • Is It Time to Re-Evaluate Our Recommendations for Screening the General Population for Risk for Type 1 Diabetes? – Prof. Desmond Schatz, MD (United States of America) • Cost Effectiveness of Screening and Immune Interventions in Type 1 – Prof. Shweta Mital (Canada) This episode is an essential listen for endocrinologists, diabetologists, pediatric specialists, and diabetes researchers looking to better understand the evolving landscape of Type 1 diabetes screening strategies and preventive therapies. Enjoy the listen! This podcast was created using AI to provide a quick and insightful summary of an ATTD 2026 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information. ATTD 2026, the 19th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on 11–14 March 2026 in Barcelona. https://attd.kenes.com

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related